【】

发布时间：2025-09-11 20:53:11 来源：都市天下脉观察 作者：百科

• Facebook
• Twitter
• Flipboard
• Comments
• Print
• Email

Dr. Jay Bhattacharya says cancer vaccine research showing 'promising' results

Fox News senior medical analyst Dr. Marc Siegel discusses Health and Human Services Secretary Robert F. Kennedy Jr. cancelling funding for mRNA vaccination contracts due to lack of public trust.

An experimental cancer vaccine has shown promise in keeping certain cancers from coming back.

In a phase 1 clinical trial led in part by the UCLA Health Jonsson Comprehensive Cancer Center, researchers tested the vaccine (ELI-002 2P) with 25 patients who had been treated for pancreatic and colorectal cancer.

The patients had all undergone surgery to remove tumors and showed "signs of minimal residual disease" or traces of DNA, putting them at a high risk of recurrence, according to a UCLA press release.

WOMAN BEATS DEADLY BRAIN CANCER WITH INVESTIGATIONAL CELL THERAPY: 'TRULY AMAZING'

More than 80% of pancreatic cancer patients experience recurrence of the disease after surgery, research shows — and for 40% to 50%, this happens within the first year.

For colorectal cancer, the recurrence rate is between 30% and 50% and is most likely to occur within the first two years after surgery.

In a phase 1 clinical trial led in part by the UCLA Health Jonsson Comprehensive Cancer Center, researchers tested the vaccine with 25 patients who had been treated for pancreatic and colorectal cancer. (iStock)

Mutations in the KRAS gene are responsible for half of colorectal cancers and more than 90% of pancreatic cancers. The vaccine, which targets those mutations, was given via a series of injections to activate an immune response in the lymph nodes.

A majority (21 out of 25) of the patients generated "KRAS-specific T cells," which indicates a stronger immune response. The ones with higher T-cell responses showed a longer relapse-free survival compared to those with lower responses, the researchers found.

MAN'S DEADLY BRAIN CANCER TUMOR DISAPPEARS AFTER EXPERIMENTAL DRUG TRIAL

For three colorectal cancer patients and three pancreatic cancer patients, the vaccine appeared to remove all disease biomarkers.

Among the patients who showed the strongest immune response, a majority were still cancer-free nearly 20 months after receiving the vaccine.

The findings were published in Nature Medicine.

A majority (21 out of 25) of the patients generated "KRAS-specific T cells," which indicates a stronger immune response.  (iStock)

"This is an exciting advance for patients with KRAS-driven cancers, particularly pancreatic cancer, where recurrence after standard treatment is almost a given and effective therapies are limited," said first author of the study, Zev Wainberg, M.D., professor of medicine at the David Geffen School of Medicine at UCLA and researcher in the UCLA Health Jonsson Comprehensive Cancer Center, in the release. 

"We observed that patients who developed strong immune responses to the vaccine remained disease-free and survived for much longer than expected."

"The new cancer vaccine from UCLA is very promising as a major tool against these cancers."

相关文章